CKAP2L promotes non-small cell lung cancer progression through regulation of transcription elongation
Authors
Monteverde, TizianaSahoo, Sudhakar
La Montagna, Manuela
Magee, Peter
Shi, Lei
Lee, David
Sellers, Robert
Baker, Alexander
Leong, Hui Sun
Fassan, M.
Garofalo, Michela
Affiliation
CRUK MI, University of Manchester.Issue Date
2021
Metadata
Show full item recordAbstract
Chromosomal instability (CIN) is a driver of clonal diversification and intra-tumor heterogeneity, providing genetic diversity that contributes to tumor progression. It is estimated that ∼80% of solid cancers, including non-small cell lung cancer (NSCLC), exhibit features of CIN, which affects tumor growth and response to therapy. However, the molecular mechanisms connecting CIN to tumor progression are still poorly understood. Through an RNAi screen performed on genes involved in CIN and overexpressed in human lung adenocarcinoma samples, we identified the cytoskeleton-associated protein 2-like (CKAP2L) as a potential oncogene that promotes lung cancer proliferation and growth in vitro and in vivo. Mechanistically, CKAP2L directly interacted with RNA Pol II and regulated transcription elongation of key genes involved in spindle assembly checkpoint, chromosome segregation, cell cycle, and E2F signaling. Furthermore, depletion of CKAP2L increased the sensitivity of NSCLC cells to alvocidib, a pan CDK inhibitor, leading to a significant reduction of cell proliferation and an increase in cell death. Altogether, these findings shed light on the molecular mechanisms through which CKAP2L, a protein involved in CIN, promotes cancer progression and suggest that its inhibition represents a novel therapeutic strategy in NSCLC.Citation
Monteverde T, Sahoo S, La Montagna M, Magee P, Shi L, Lee D, et al. CKAP2L promotes non-small cell lung cancer progression through regulation of transcription elongation. Cancer Res. 2021.Journal
Cancer ResearchDOI
10.1158/0008-5472.Can-20-1968PubMed ID
33472893Additional Links
https://dx.doi.org/10.1158/0008-5472.Can-20-1968Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/0008-5472.Can-20-1968
Scopus Count
Collections
Related articles
- NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling.
- Authors: Jin X, Liu X, Zhang Z, Xu L
- Issue date: 2020 Dec 10
- Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
- Authors: Zhang K, Wang J, Yang L, Yuan YC, Tong TR, Wu J, Yun X, Bonner M, Pangeni R, Liu Z, Yuchi T, Kim JY, Raz DJ
- Issue date: 2018 Oct 22
- ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
- Authors: Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, Li J, Wang J, Shi W, Wang L, Zheng Y, Sun Y
- Issue date: 2021
- CKAP2L, transcriptionally inhibited by FOXP3, promotes breast carcinogenesis through the AKT/mTOR pathway.
- Authors: Chi F, Chen L, Jin X, He G, Liu Z, Han S
- Issue date: 2022 Mar 15
- DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
- Authors: Wang Z, Luo Z, Zhou L, Li X, Jiang T, Fu E
- Issue date: 2015 Oct